Xenetic Biosciences, Inc. (XBIO) Stock Price

XBIOStock

$3.98+39.65%52W

Market Cap$9.33M

P/E—

PEG Ratio—

Div yield—

Beta2.16

XBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)56.71%

Price vs S&P 500 (4W)48.08%

VGM Score80.83

Book Value / Share (Quarterly)$3.03

P/TBV (Annual)1.46x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)20.29%

Cash Flow / Share (Quarterly)$-0.79

Price vs S&P 500 (YTD)70.59%

Gross Margin (TTM)98.68%

Net Profit Margin (TTM)-70.03%

EPS (TTM)$-1.24

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-1.24

Revenue Growth (5Y)46.57%

EPS (Annual)$-1.58

ROI (Annual)-36.25%

Gross Margin (Annual)97.89%

Net Profit Margin (5Y Avg)-256.27%

Cash / Share (Quarterly)$3.20

Revenue Growth QoQ (YoY)36.01%

ROA (Last FY)-32.05%

Revenue Growth TTM (YoY)23.52%

EBITD / Share (TTM)$-1.27

ROE (5Y Avg)-44.62%

Operating Margin (TTM)-75.05%

Cash Flow / Share (Annual)$-1.00

P/B Ratio1.09x

P/B Ratio (Quarterly)0.88x

Net Income / Employee (Annual)$-1,340,400

EV / Revenue (TTM)0.07x

Net Interest Coverage (TTM)-4.23x

ROA (TTM)-33.48%

EPS Incl Extra (Annual)$-1.58

Current Ratio (Annual)8.32x

Quick Ratio (Quarterly)7.67x

3-Month Avg Trading Volume0.03M

52-Week Price Return39.65%

Revenue / Employee (TTM)$1,595,000

Tangible BV / Share (Quarterly)$14.05

P/S Ratio (Annual)2.54x

Asset Turnover (Annual)0.36x

52-Week High$13.93

Operating Margin (5Y Avg)-265.97%

EPS Excl Extra (Annual)$-1.58

Tangible BV CAGR (5Y)75.69%

26-Week Price Return68.64%

Quick Ratio (Annual)8.14x

13-Week Price Return29.22%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.93x

Enterprise Value$213,100

Revenue / Share Growth (5Y)20.54%

Asset Turnover (TTM)0.48x

Book Value / Share Growth (5Y)-25.48%

Revenue / Employee (Annual)$1,488,200

Pretax Margin (Annual)-90.07%

Cash / Share (Annual)$3.44

3-Month Return Std Dev59.64%

Net Income / Employee (TTM)$-1,117,000

ROE (Last FY)-36.25%

Net Interest Coverage (Annual)-22.81x

EPS Basic Excl Extra (Annual)$-1.58

P/FCF (TTM)1.48x

Receivables Turnover (TTM)5.06x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.24

Receivables Turnover (Annual)5.06x

ROI (TTM)-39.28%

P/S Ratio (TTM)2.37x

Pretax Margin (5Y Avg)-256.27%

Revenue / Share (Annual)$1.75

Tangible BV / Share (Annual)$14.05

Price vs S&P 500 (52W)21.09%

Year-to-Date Return83.41%

5-Day Price Return4.46%

EPS Normalized (Annual)$-1.58

ROA (5Y Avg)-40.29%

Net Profit Margin (Annual)-90.07%

Month-to-Date Return57.00%

Cash Flow / Share (TTM)$-2.92

EBITD / Share (Annual)$-1.67

Operating Margin (Annual)-95.23%

ROI (5Y Avg)-44.62%

EPS Basic Excl Extra (TTM)$-1.24

P/TBV (Quarterly)1.46x

P/B Ratio (Annual)0.67x

Pretax Margin (TTM)-70.03%

Book Value / Share (Annual)$3.23

Price vs S&P 500 (13W)27.27%

Beta2.16x

P/FCF (Annual)5.11x

Revenue / Share (TTM)$1.39

ROE (TTM)-39.28%

52-Week Low$1.90

vGradeA

gGradeB

mGradeA

vgmGradeA

XBIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Mar 12, 2026	-$0.52	-$0.22	+57.69%(+$0.30)
Q3 2025	Nov 12, 2025	-$0.49	-$0.33	+32.65%(+$0.16)
Q2 2025	Aug 12, 2025	-$0.64	-$0.45	+29.69%(+$0.19)
Q1 2025	May 13, 2025	-$0.72	-$0.59	+18.06%(+$0.13)

XBIO Analyst Recommendations

Nov 2025

Dec 2025

Jan 2026

Feb 2026

2.17

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
XBIOXenetic Biosciences, Inc.	A	B	A	$3.98
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Xenetic Biosciences, Inc.

Xenetic Biosciences Inc is a biopharmaceutical company developing DNase-based therapies for difficult-to-treat cancers. The company's proprietary DNase technology targets neutrophil extracellular traps (NETs) to enhance the effectiveness of existing cancer treatments and immunotherapies. Xenetic is advancing a systemic DNase program as an adjunctive therapy for pancreatic cancer and other metastatic solid tumors.